$OMER

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

US futures rise as Fed Chair Warsh's silence is interpreted as dovish, cutting October rate hike odds. Tesla gains 5% after unveiling its 'flying' Roadster. Oil prices fluctuate following Trump's comments on Iran. S&P futures up 0.1%, Nasdaq and Dow futures down 0.2%. Tesla, Fox Corp, Mobileye, and Semtech rise premarket, while Omeros, Travelers, and Truist Financial fall. Goldman Sachs upgrades Zeta Global, sending shares up 4.6%.

Omeros Corporation (OMER) received a negative opinion from the EMA's CHMP on its EU marketing application for narsoplimab, despite FDA approval in the U.S. The company will need additional data or a revised submission to pursue EU approval. According to the company, this decision impacts its international rollout while U.S. commercialization continues.

Cantor Fitzgerald maintained an Overweight rating on Omeros with a $22 price target, suggesting 16.5% upside from the Oct 13 close of $18.88. The firm cited Omeros's strong pipeline, particularly narsoplimab and OMS1029, and positive market sentiment as key reasons.

Omeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.

Natera (NTRA) and Omeros (OMER) shares rose on Tuesday, with NTRA hitting an all-time high and OMER reaching a 5-year peak. NTRA's cancer test received Japanese regulatory approval, while OMER was upgraded by Cantor Fitzgerald due to optimism about its lead drug's potential. NTRA is up 5%, OMER up 12% at the time of writing.

Omeros Corporation (OMER) shares rose 5% after hours on optimism about its deal with Novo Nordisk and drug launches. Q4 net income was $86.5M, up from a $31.4M loss in 2024, including a $237.6M gain from the zaltenibart transaction. The company expects milestone payments and royalties from Novo Nordisk and anticipates positive cash flow by 2027.

Cancelmo Peter B (VP, General Counsel) sold 50,000 shares of OMEROS CORP (OMER) at an average of $18.59 ($18.54–$18.65, $0.93M total) across 2 trades over 2026-08-28 to 2026-08-31.

HANISH ARNOLD C sold 15,000 shares of OMEROS CORP (OMER) at an average of $18.81 ($18.53–$19.02, $0.28M total) across 3 trades over 2026-08-26 to 2026-08-27.

Omeros Corp's (NASDAQ:OMER) VP of Finance, David Borges, sold 10,906 shares for $206,804 after exercising options. Shares were sold at $18.95-$19.10, with options exercised at $2.94-$3.93. Omeros reported Q2 earnings of $0.02 per share, beating estimates, and revenue of $28.5M, also exceeding forecasts, driven by its drug YARTEMLEA.